On Wednesday, advisors to the American Centers for Disease Control and Prevention (CDC) voted to recommend the Jynneos vaccine from Bavarian Nordic for all adults who might contract mpox during an outbreak.

The panel of independent experts unanimously approved the use of two doses of the vaccine and the formalization of the interim recommendations made by the CDC during the American mpox outbreak.

The committee′s proposal is supported by research showing vaccine efficacy of 36%-86% for partial immunization and 66%-83% for full vaccination in people with no serious adverse effects.

The ideal route of administration for adults during the outbreak is an intradermal injection of Jynneos, which is between the layers of skin. Nevertheless, subcutaneous injections, which are administered below the skin, are also permitted.

Based on the panel′s decision, previously approved Emergent BioSolutions smallpox vaccine may lose ground to Bavarian Nordic′s vaccine due to its severe side effects.

According to government statistics, more than 29,000 instances of mpox were reported in the US last year, including two fatalities. Mpox, spreads through close contact, and symptoms include pus-filled skin lesions and flu-like symptoms. 

The World Health Organization (WHO) earlier this month maintained its highest level of alert for the disease, citing continued transmission in some countries. Hence still, it remains a public health emergency of international concern.

(Source: https://www.reuters.com/business/healthcare-pharmaceuticals/cdc-panel-recommends-bavarian-nordics-mpox-vaccine-all-adults-risk-2023-02-22/)